Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the

On Thursday evening, the Los Angeles Lakers beat the Boston Celtics (at home) by a score of 117-96. LeBron James and Anthony Davis combined for 44 points, 22 r

Savannah's Clay Johnson, lead singer of the Fabulous Equinox Orchestra, competes in the 2025 ATC, the first time in a decade there will be a local contestant

The Bears are not retaining nicklebacks coach David Overstreet, running backs coach Chad Morton or cornerbacks coach Jon Hoke, according to multiple reports. Hoke helped make Jaylon Johnson an NFL All-Pro cornerback; Overstreet helped develop Kyler Gordon into a standout nickelback.

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its extensive supply chain?

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and challenges as it positions itself for long-term growth. Recent financial reports and analyst assessments paint a picture of a company leveraging its strong oncology portfolio and innovative medicine segment to offset headwinds in other areas.

The Chicago Bears already have their coach and quarterback of the future. Could they add their running back of the future in the NFL Draft? Chicago will pick at No. 10 in the April draft and should be able to add a pretty big piece.

So far, Louisville holds five of commitments in the Class of 2026: Chiefland (Fla.) HS edge rusher Jon Adams, Aurora (Ind.) South Dearborn linebacker Brady Ballart, Crestwood (Ky.) South Oldham defensive lineman Sam Dawson, Fort Thomas (Ky.) Highlands offensive lineman Max Merz, Galloway (Oh.) Westland two-way prospect Emoni Smith.

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.